Research advances of factors and mechanisms for therapeutic efficacy of rituximab for primary membranous nephropathy
Primary membranous nephropathy （PMN） is a kidney-specific autoimmune disease mediated by autoantibodies. Although rituximab （RTX） has been widely applied as a first-line treatment for PMN, 20%-40% patients are non-responsive to RTX. High disease activity, severe renal lesions and low RTX bioavailabi...
Bewaard in:
| Hoofdauteurs: | , |
|---|---|
| Formaat: | Artigo |
| Taal: | Chinês |
| Gepubliceerd in: |
Editorial Department of Journal of Clinical Nephrology
2024-09-01
|
| Reeks: | Linchuang shenzangbing zazhi |
| Onderwerpen: | |
| Online toegang: | http://www.lcszb.com/cn/article/doi/10.3969/j.issn.1671-2390.2024.09.010 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|